Paper - WANFANG MED ONLINE

You Position: Home > Paper

重症肺炎和脓毒血症抗凝治疗的时机和策略

( views:106, downloads:1048 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 3

DOI:: 10.3760/cma.j.issn.1001–0939.2015.03.015

Key Word:: No keyword available

Abstract：重症社区获得性肺炎(community-acquired pneumonia,CAP)是感染性疾病患者死亡最常见的病因之一,病死率可达30％[1],而入住ICU后的重症CAP的病死率可高达58％[2],脓毒性休克患者的病死率可达50％以上[3].随着抗生素耐药率的增加,病死率增高,而且即使应用新型抗生素也无法显著改善患者的预后,故需要进一步研究辅助治疗方法的应用[4].

Reference

[1]Marcos I, Restrepo,Eric M, Mortensen,Jose A, Velez,etc.A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.[J].2008,133(3).
[2]Goda, Choi,Jorrit-Jan H, Hofstra,Joris J T H, Roelofs,etc.Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats.[J].2007,35.
[3]Dhainaut JF,Fisher CJ Jr,Ely EW,etc.Efficacy and safety of recombinant human activated protein C for severe sepsis.[J].2001,344(10).
[4]J C, Marshall.Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome.[J].2001,29(7 Suppl).
[5]Laurent Robriquet,François Collet,Antoine Tournoys,etc.Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response[J].2006,7(1).
[6]Anita Rijneveld.Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.[J].2006,34(6).
[7]C F, Moldow,R R, Bach,K, Staskus,etc.Induction of endothelial tissue factor by endotoxin and its precursors.[J].1993,70(4).
[8]Annane,D.,Timsit,J.-F.,Megarbane,B.,etc.Recombinant human activated protein c for adults with septic shock: A randomized controlled trial[J].2013,187(10).
[9]G, Choi,M J, Schultz,J W O, van Till,etc.Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection.[J].2004,24.
[10]Albertine KH,Bastarache JA,Matthay MA,etc.The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor.[J].2007,62(7).
[11]Schultz MJ,Roelofs JJ,Florquin S,etc.Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats.[J].2008,36(1).
[12]Anzueto A,Restrepo MI.Severe community-acquired pneumonia.[J].2009,23(3).
[13]G Choi,M J Schultz,M Levi,etc.Protein C in pneumonia[J].2005,60(8).
[14]L, Engelmann,S, Petros.[Identification of patients suitable for therapy with activated Protein C].[J].2006,55 Suppl 1.
[15]Curley MA,Flori H,Sapru A,etc.Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury.[J].2010,36(1).
[16]Derek C, Angus.Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party.[J].2012,16(1).
[17]Andreas Gunther,Parvin Mosavi,Sabine Heinemann.Alveolar Fibrin Formation Caused by Enhanced Procoagulant and Depressed Fibrinolytic Capacities in Severe Pneumonia Comparison with the Acute Respiratory Distress Syndrome[J].2000,161(2).
[18]Anita W, Rijneveld,Sandrine, Florquin,Paul, Bresser,etc.Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia.[J].2003,102.
[19]van der Poll T,Weverling GJ,Millo J,etc.Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.[J].2004,59(2).
[20]G, Choi,A P J, Vlaar,M, Schouten,etc.Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation.[J].2007,30.
[21]Pet?j?,J.,Ruuskanen,O.,Heikinheimo,M.,etc.Enhanced thrombin generation and depressed anticoagulant function in children with pneumonia[J].2012,101(9).
[22]Marcello Di Nisio,Francesco Baudo,Benilde Cosmi,etc.Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)[J].2012,129(5).
[23]Wunderink RG,Rello J,Waterer GW.Management of community-acquired pneumonia in adults.[J].2011,183(2).
[24]Pierre-François Laterre,Steven M Opal,Edward Abraham,etc.A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia[J].2009,13(2).
[25]Roelofs JJ,Van Den Boogaard FE,Brands X,etc.Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia.[J].2011,9(1).
[26]Abraham E,Shu V,Zwingelstein C,etc.Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.[J].2003,290(2).
[27]Ohno R,Matsuda T,Saito H,etc.Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.[J].2007,5(1).
[28]Ranieri,V.M.,Thompson,B.T.,Barie,P.S.,etc.Drotrecogin alfa (activated) in adults with septic shock[J].2012,366(22).
[29]Ivanciu L,Taylor-FB Jr,Peer G,etc.Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor.[J].2007,171(3).
[30].Epidemiology of severe sepsis[J].2014,5(1).
[31]E, Abraham,K, Reinhart,P, Svoboda,etc.Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.[J].2001,29(11).
[32]Johannes N Hoffmann.Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis.[J].2004,32(9).
[33]Rosemarijn, Renckens,Joris J T H, Roelofs,Peter I, Bonta,etc.Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia.[J].2007,109(4).
[34]Wittebole X,Perrotin D,LaRosa S,etc.Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.[J].2011,183(11).
[35]M, Levi,C H, Toh,J, Thachil,etc.Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.[J].2009,145(1).
[36]Yuanlin Song.Increased Plasminogen Activator Inhibitor-1 Concentrations in Bronchoalveolar Lavage Fluids Are Associated with Increased Mortality in a Cohort of Patients with Pseudomonas aeruginosa.[J].2007,106(2).
[37]Roux J,Goolaerts A,Miyazawa B,etc.PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice.[J].2011,66(9).
[38]Toshimitsu Hamasaki,Kazuma Yamakawa,Hiroshi Tanaka,etc.Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis[J].2013,39(4).
[39]Levi M,Wiersinga WJ,van der Poll T,etc.Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis).[J].2011,9(10).
[40]Heinrichs H,Singer P,Novak I,etc.Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.[J].2001,286(15).
[41]Schultz,M.,vanderPoll,T.,Levi,M..New insights into pathways that determine the link between infection and thrombosis[J].2012,70(3).
[42]Fourrier F,Guery BP,Tournoys A,etc.Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury.[J].2004,21(5).